Literature DB >> 31047325

Tomographic Biomarkers Predicting Progression to Fibrosis in Treated Neovascular Age-Related Macular Degeneration: A Multimodal Imaging Study.

Giuseppe Casalino1, Michael R Stevenson2, Francesco Bandello3, Usha Chakravarthy4.   

Abstract

PURPOSE: To describe the photoreceptor-retinal pigment epithelium (RPE) interface changes and to analyze the relationships between these features and hyperreflective material (HRM) with scarring and atrophy at the macula of patients with neovascular age-related macular degeneration (nAMD).
DESIGN: Retrospective single-center observational study. PARTICIPANTS: A total of 150 eyes from 144 patients with naive nAMD were included.
METHODS: All patients had OCT (HRA-OCT Spectralis, Heidelberg Engineering, Heidelberg, Germany) at baseline and at 1, 3, 6, and 12 months. Macular scar and macular atrophy (MA) were determined on multimodal imaging, including color fundus (CF) and near-infrared imaging at baseline and month 12 (M12). MAIN OUTCOME MEASURES: Change in HRM type (undefined and well-defined) and location, development of fibrotic or nonfibrotic macular scar, MA, and best-corrected visual acuity (BCVA) at M12.
RESULTS: At baseline, eyes with fibrin on CF had thicker and wider HRM on OCT that correlated strongly with presence of undefined HRM. The proportion of eyes with undefined HRM fell dramatically by month 1 but well-defined HRM increased. At M12 defined HRM was strongly associated with macular scar (chi-square, 82.1; P < 0.001). Ordinal regression showed that both the thickness and the width of HRM were significant risk factors for development of fibrotic scar (P < 0.001 and P = 0.02) but not nonfibrotic scars (P = 0.67 and P = 0.65). Fibrotic macular scar (P = 0.001) but not nonfibrotic scar (P = 0.129) negatively affected visual acuity at M12. Ordinal regression showed that the risk factors for progression to MA were reticular pseudodrusen and thinner HRM (P = 0.017 and P = 0.028, respectively). MA negatively affected BCVA at M12 (P < 0.001).
CONCLUSION: Our study supports the role of HRM as an important biomarker for the evolution of macular scar and atrophy in patients with nAMD undergoing treatment with anti-VEGF therapies. Undefined HRM can resolve with treatment, whereas well-defined HRM likely contains vascular complexes and fibrotic elements.
Copyright © 2017 American Academy of Ophthalmology. Published by Elsevier Inc. All rights reserved.

Entities:  

Year:  2017        PMID: 31047325     DOI: 10.1016/j.oret.2017.08.019

Source DB:  PubMed          Journal:  Ophthalmol Retina        ISSN: 2468-6530


  9 in total

1.  The identification of activity of choroidal neovascularization complicating angioid streaks.

Authors:  Alessandro Marchese; Chiara Giuffrè; Maria Vittoria Cicinelli; Alessandro Arrigo; Francesco Bandello; Maurizio Battaglia Parodi
Journal:  Eye (Lond)       Date:  2021-05-10       Impact factor: 4.456

2.  The transcriptome of peripheral blood mononuclear cells in patients with clinical subtypes of late age-related macular degeneration.

Authors:  Yousif Subhi; Marie Krogh Nielsen; Christopher Rue Molbech; Charlotte Liisborg; Helle Bach Søndergaard; Finn Sellebjerg; Torben Lykke Sørensen
Journal:  Immun Ageing       Date:  2019-08-15       Impact factor: 6.400

3.  Early Ophthalmic Changes in Macula Does Not Correlate with Visual Function.

Authors:  Divya Narayanan; Garrick Wallstrom; John Rodriguez; Donna Welch; Matthew Chapin; Paul Arrigg; Rajkumar Patil; Mark Abelson
Journal:  Clin Ophthalmol       Date:  2020-09-03

4.  Human umbilical cord mesenchymal stem cell-derived exosomal miR-27b attenuates subretinal fibrosis via suppressing epithelial-mesenchymal transition by targeting HOXC6.

Authors:  Dongli Li; Junxiu Zhang; Zijia Liu; Yuanyuan Gong; Zhi Zheng
Journal:  Stem Cell Res Ther       Date:  2021-01-07       Impact factor: 6.832

5.  Transcriptomic analysis of choroidal neovascularization reveals dysregulation of immune and fibrosis pathways that are attenuated by a novel anti-fibrotic treatment.

Authors:  Alice Brandli; Fay L Khong; Roy C K Kong; Darren J Kelly; Erica L Fletcher
Journal:  Sci Rep       Date:  2022-01-17       Impact factor: 4.379

6.  Morphologic and Microvascular Differences Between Macular Neovascularization With and Without Subretinal Fibrosis.

Authors:  Philipp Ken Roberts; Markus Schranz; Alice Motschi; Sylvia Desissaire; Valentin Hacker; Michael Pircher; Stefan Sacu; Wolf Buehl; Christoph Konrad Hitzenberger; Ursula Schmidt-Erfurth
Journal:  Transl Vis Sci Technol       Date:  2021-12-01       Impact factor: 3.283

7.  Utilization of deep learning to quantify fluid volume of neovascular age-related macular degeneration patients based on swept-source OCT imaging: The ONTARIO study.

Authors:  Simrat K Sodhi; Austin Pereira; Jonathan D Oakley; John Golding; Carmelina Trimboli; Daniel B Russakoff; Netan Choudhry
Journal:  PLoS One       Date:  2022-02-14       Impact factor: 3.240

8.  Associations of Variation in Retinal Thickness With Visual Acuity and Anatomic Outcomes in Eyes With Neovascular Age-Related Macular Degeneration Lesions Treated With Anti-Vascular Endothelial Growth Factor Agents.

Authors:  Rebecca N Evans; Barnaby C Reeves; Maureen G Maguire; Daniel F Martin; Alyson Muldrew; Tunde Peto; Chris Rogers; Usha Chakravarthy
Journal:  JAMA Ophthalmol       Date:  2020-10-01       Impact factor: 7.389

9.  Fibrotic Changes and Endothelial-to-Mesenchymal Transition Promoted by VEGFR2 Antagonism Alter the Therapeutic Effects of VEGFA Pathway Blockage in a Mouse Model of Choroidal Neovascularization.

Authors:  Franco Aparecido Rossato; Yu Su; Ashley Mackey; Yin Shan Eric Ng
Journal:  Cells       Date:  2020-09-09       Impact factor: 6.600

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.